Tesamorelin + Ipamorelin: The Dual-Receptor GH Stack
Two peptides, two receptors, one growth-hormone axis. Tesamorelin mimics GHRH; ipamorelin mimics ghrelin. We separate the proven mechanism from the viral "stacking beats either alone" claim.
What's in the Stack
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH). It binds the GHRH receptor on pituitary somatotrophs, driving synthesis and pulsatile release of the body's own growth hormone. It is FDA-approved (as Egrifta) to reduce visceral fat in HIV-associated lipodystrophy.
Ipamorelin is a selective agonist of the ghrelin receptor (GHS-R1a) — the same receptor the hunger hormone ghrelin uses to trigger GH release. In its founding study it released GH as potently as GHRP-6 but, unlike older secretagogues, without raising ACTH or cortisol.
Because GHRH analogs and ghrelin mimetics act through two distinct receptors on the same cell, co-administering a GHRH with a GH-releasing peptide produces a greater, supra-additive GH pulse than either alone — a synergy demonstrated in controlled human studies.
The human synergy trials paired GHRH with GHRP-2 or GHRP-6 — not tesamorelin with ipamorelin. The two-receptor rationale transfers, but no published trial has tested this exact pair, and the effect is modulated by age, sex and body fat. Treat "beats either alone" as mechanism-plausible, not proven for this stack.
What the Data Shows
Key Takeaways
- Tesamorelin is a GHRH analog that binds the GHRH receptor; ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist. They act on two different receptors of the growth-hormone axis.
- In HIV-associated lipodystrophy trials, tesamorelin reduced visceral adipose tissue by roughly 15% versus placebo over 26 weeks (NEJM 2007; confirmed in a pooled phase 3 analysis, JCEM 2010).
- Ipamorelin was characterized as the first selective GH secretagogue — releasing GH without the ACTH and cortisol spikes seen with earlier GHRPs (Eur J Endocrinol 1998).
- Co-administering a GHRH with a GH-releasing peptide produces a supra-additive GH pulse in controlled human studies — the physiological basis for "dual-receptor" stacking (Am J Physiol 2009; JCEM 2008).
- Both are peptides that stimulate the body’s own growth hormone rather than injecting HGH directly.
- No published clinical trial has tested the tesamorelin + ipamorelin combination specifically — the synergy evidence comes from GHRH paired with GHRP-2 / GHRP-6, not this exact pair.
- Whether the two-receptor synergy translates into meaningful body-composition or performance outcomes (beyond a larger acute GH pulse) has not been established for this stack.
- The magnitude of GHRH / GHRP synergy varies with age, sex and body fat, so any "beats either alone" effect is not uniform across people (JCEM 2008).
- Long-term safety of chronic combined GH-axis stimulation is not defined; tesamorelin is approved only for HIV lipodystrophy and ipamorelin was never approved for any use.
- Optimal dosing, timing and duration for a combined protocol have not been studied in controlled trials.
Frequently Asked Questions
What is the tesamorelin and ipamorelin stack?
It is the practice of combining tesamorelin — a growth-hormone-releasing hormone (GHRH) analog — with ipamorelin, a selective ghrelin-receptor (GHS-R1a) agonist. The goal is to stimulate growth hormone through two different receptors of the pituitary GH axis at once, rather than through one.
Does stacking tesamorelin and ipamorelin work better than either alone?
Mechanistically it is plausible: controlled human studies show that pairing a GHRH with a GH-releasing peptide produces a larger, supra-additive GH pulse than either compound by itself. However, those trials used GHRP-2 or GHRP-6, not ipamorelin, and no published trial has tested the tesamorelin + ipamorelin pair specifically. The synergy is a reasonable extrapolation, not a proven result for this exact stack.
How do tesamorelin and ipamorelin work differently?
Tesamorelin binds the GHRH receptor, mimicking the hypothalamic hormone that tells the pituitary to make and release GH. Ipamorelin binds the ghrelin receptor (GHS-R1a) — the same one the hunger hormone ghrelin uses — triggering GH release through a separate pathway. Two receptors, one growth-hormone axis.
Is ipamorelin safer than older GH secretagogues?
In its founding study, ipamorelin released growth hormone about as potently as GHRP-6 but, unlike GHRP-6 and GHRP-2, did not meaningfully raise ACTH or cortisol — earning it the label "the first selective growth hormone secretagogue." That selectivity is why it is often chosen for stacks. Long-term human safety data, however, remain limited.
Are tesamorelin and ipamorelin FDA-approved?
Tesamorelin (brand name Egrifta) is FDA-approved only to reduce excess abdominal fat in people with HIV-associated lipodystrophy. Ipamorelin has never been approved for any medical use. Combined use is off-label and research-only.
🔬 Research-Grade Source
Swiss Chems publishes third-party HPLC COAs for selected products — vendor-published, a claim to verify. HighPeptides' primary vendor reference for peptides.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Peer-Reviewed References
Educational purposes only. Not medical advice.
Tesamorelin is FDA-approved only for HIV-associated lipodystrophy; ipamorelin is not approved for any use. Nothing here is a recommendation to use, dose, or combine them.
Always consult a qualified healthcare provider before considering any peptide.